Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
366
resultados
Última actualización
30/10/2026 [08:23:00]
Resultados 200 a 225 de 366
Resumen de: CN122790086A
0001 本发明公开了一种检测tau蛋白的抗体及其应用，涉及抗体领域。本发明公开的检测tau蛋白的抗体包括重链互补决定区和轻链互补决定区，该抗体为tau蛋白的检测提供了重要的原料来源，基于该抗体的检测，灵敏度高、特异性强，有助于阿尔茨海默病等相关疾病的预测、诊断、动态监测及预后评估，具有非常高的临床应用价值。
Resumen de: AU2025211997A1
Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.
Resumen de: US2019227064A1
0001 The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: US2021063416A1
A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
Resumen de: CN122768451A
0001 本发明属于神经退行性疾病治疗技术领域，具体涉及通过调控神经元Sortilin‑1（SORT1）蛋白的表达或功能活性，预防、治疗阿尔茨海默病（Alzheimer's Disease,·AD）的方法与药物组合物；同时涉及调控神经元‑小胶质细胞信号通路，维持神经元内体稳态、抑制小胶质细胞异常促炎活化、减轻神经炎症、保护神经元功能的技术方案。
Resumen de: CN122772104A
本发明提供了一种抗eMTBR‑tau243蛋白片段的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的抗eMTBR‑tau243蛋白片段的单克隆抗体，能够特异性结合tau蛋白片段（aa225‑242），以及包含这个片段的tau蛋白片段（aa1‑256）以及全长tau蛋白（2N4R，aa1‑441），能够用于上述蛋白检测产品的制备。
Resumen de: KR20260138113A
본 발명은 단백질의 초기 응집 거동을 관찰할 수 있는 단백질의 응집 거동 관찰 장치 및 이를 이용한 단백질의 응집 거동 관찰 방법에 관한 것이다.
Resumen de: CN122772105A
发明公开了一种抗人Aβ40的抗体及其应用。所述抗体含重链可变区VH和轻链可变区VL；所述VH包含HCDR1、HCDR2和HCDR3，所述VL包含LCDR1、LCDR2和LCDR3；所述HCDR1‑HCDR3分别包含如SEQ ID NO:1‑3所示的氨基酸序列，所述LCDR1‑LCDR3分别包含如SEQ ID NO:4‑6所示的氨基酸序列。本发明的抗体灵敏性高、特异性好，基于该抗体对人Aβ40进行免疫检测，操作简单、灵敏度高、特异性强，可实现人Aβ40的快速检测，对评估人Aβ40具有重要意义。
Resumen de: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Resumen de: CN122772974A
本发明涉及生物医药技术领域，尤其是涉及基于SERPING1的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPING1为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: CN122772976A
0001 本发明涉及生物医药技术领域，尤其是涉及基于PRDX4的PASC相关心血管系统症状风险评估应用。本发明提供了一种以PRDX4为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: WO2025176707A1
The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Resumen de: WO2025144847A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: CN122775828A
0001 本发明公开一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用。本发明的方法通过主客观权重协同优化与数据标准化处理构建科学评价模型，采用合适的综合评分法实现了对加工黄精的综合质量评价，进而指导工艺参数优化，同时提升主要活性成分保留率与稳定性，实现质量与效率的双重提升。本发明还进行了加工黄精的提取物在改善衰老动物记忆下降中的功效研究，通过构建的具有阿尔茨海默病特征的动物模型的功效相关研究结果表明，包含黄精粗多糖或黄精粗皂苷的黄精加工产品能够有效改善运动障碍、认知功能障碍和脑区Aβ病理性斑块的蓄积，同时具有显著的脑部细胞凋亡抑制作用。
Resumen de: US20260272976A1
0000 Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Resumen de: US20260276648A1
Methods for identifying tumor tissue and determining a margin of a tumor to be resected in a subject are disclosed within. The methods utilize guanidinoacetic acid (GAA) as a tissue biomarker of malignant brain tumors. The presently disclosed subject matter further relates to methods for providing a diagnosis or prognosis about a cancer in a subject.
Resumen de: US20260276657A1
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
Resumen de: AU2026205448A1
Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract
Resumen de: AU2025235500A1
Methods for improving brain function and increasing brain activity by oral administration of choline are provided. Compositions including unit doses of choline sufficient to provide improved brain function and increasing brain activity are also provided. In some embodiments, it includes a method for improving brain function and/or increasing brain efficiency in a subject in need thereof, the methods comprising administering a pharmaceutical composition comprising 550 mg or greater of choline. The increases in brain efficiency are measured by functional Magnetic Resonance Imaging, as compared to placebo, when the subject is performing an N-Back task.
Resumen de: AU2025232230A1
Disclosed herein are chemical probes for unfolded, misfolded or intrinsically disordered proteins, in particular chemical probes having the structure of Formula I or salts thereof, and to the use of the probes for various applications relating to unfolded, misfolded or intrinsically disordered proteins, for example, for diagnosing or prognosing a disease or disorder associated with an unfolded, misfolded or intrinsically disordered protein.
Resumen de: US20260279589A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: US20260276625A1
Provided is a screening method for searching for a new autophagy-inducing compound. In the present invention, a new autophagy-inducing compound is searched for using at least one of the following characteristics: (1) having high binding affinity for DEAD-box RNA helicase; (2) approximating DEAD-box RNA helicase and p62 to promote interaction; and (3) promoting droplet formation of DEAD-box RNA helicase and p62.
Resumen de: US20260274931A1
Disclosed herein are methods of conducting clinical trials in Alzheimer's disease (AD). Methods of selecting a medicament and treating an AD subject are disclosed. Methods, systems, kits, and devices for selecting a subject in AD clinical trials and treatment protocols are disclosed herein.
Resumen de: US20260276655A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Nº publicación: US20260276659A1 17/09/2026
Solicitante:
MASSACHUSETTS GEN HOSPITAL [US]
The General Hospital Corporation
Resumen de: US20260276659A1
A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.
BOPI
Sede Electrónica
